The analyst also specifies that since CEO Larry Culp took charge of affairs last year, there has been an impressive focus on improving the company's cash flow and debt repayment. Culp has made quick moves in raising cash for GE and sold a few somewhat ignorable assets, including selling GE's biopharma arm to Danaher for $21 billion. Mittermaier says that to a large extent, this has informed his bullish forecast on GE.